Skip to content

Investor Relations / Press Releases

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary Additional Formats
Toggle Summary Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin Treated Patients With Persistent High Triglycerides and Chronic Kidney Disease
BEDMINSTER , N.J. and DUBLIN, Ireland , Nov. 13, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced an oral presentation titled, "Icosapent Ethyl
View HTML
Toggle Summary Real-World Data Analysis Shows That High Triglyceride Levels Are Associated With Increased Cardiovascular Events and Medical Costs
Higher Rates of Myocardial Infarction (Heart Attack) and Revascularization Procedures in Patients with High Triglycerides Were Drivers of the Composite Outcome MACE Rate 35% Higher in Patients Who, Despite Statin Therapy, Have Elevated Triglyceride Levels Cost of Health Care Nearly 15% Higher in
View HTML
Toggle Summary Amarin to Present at the Jefferies London Healthcare Conference
BEDMINSTER, N.J. , and DUBLIN, Ireland , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
View HTML
Toggle Summary Amarin Sponsors Multiple Scientific Study Presentations Scheduled For 2017 American Heart Association Scientific Sessions
Amarin Sponsors Multiple Scientific Study Presentations Scheduled For 2017 American Heart Association Scientific Sessions Presentations to Include Results of Real World Data Analysis of Patient Cardiovascular Experience from Managed Care Databases BEDMINSTER, N.J., and DUBLIN, Ireland, November 1,
View HTML
Toggle Summary Amarin Reports Third Quarter 2017 Financial Results and Provides Update on Operations
Record-High Net Product Revenue of $47.1 Million in Third Quarter Management to Host Conference Call Today at 8:00 a.m. ET BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and
View HTML
Toggle Summary Amarin to Report Third Quarter 2017 Results and Host Conference Call on November 1, 2017
BEDMINSTER, N.J. , and DUBLIN, Ireland , Oct. 25, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with
View HTML
Toggle Summary Amarin and HLS Therapeutics Announce Agreement to Commercialize Vascepa® in Canada
BEDMINSTER, N.J. , DUBLIN, Ireland , and TORONTO, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) and HLS Therapeutics Inc. ("HLS"), announced today an exclusive agreement between the parties to register, commercialize and distribute Vascepa® (icosapent ethyl) capsules in
View HTML
Toggle Summary Amarin to Present at Cantor Global Healthcare Conference
BEDMINSTER, N.J. , and DUBLIN, Ireland , Sept. 20, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
View HTML
Toggle Summary Amarin Appoints Mark W. Salyer to New Position of Chief Commercial Officer
Addition to Senior Management Team Further Strengthens Amarin for Growth
View HTML
Toggle Summary Amarin to Present at Rodman & Renshaw's Global Investment Conference
BEDMINSTER, N.J. , and DUBLIN, Ireland , Sept. 06, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
View HTML
copyright
© 2018, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
2 Pembroke House, Upper Pembroke
Street 28-32
Dublin 2, Ireland
US Investor Relations
Amarin Pharma Inc.
1430 Route 206
Bedminster, NJ 07921 USA
Telephone:
+1 908 719 1315
Fax:
+1 908 719 3012

Amarin Corporation